|By Marketwired .||
|November 7, 2012 01:26 AM EST||
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 11/07/12 -- MorphoSys AG / MorphoSys AG Reports Nine Months 2012 Results . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results according to International Financial Reporting Standards (IFRS) for the nine months ending September 30, 2012. The most important event during the third quarter was the publication of excellent safety and efficacy data for MOR103 in rheumatoid arthritis (RA), the most advanced proprietary program in MorphoSys's pipeline.
"During the first nine months of 2012, we made significant progress with our pipeline of new therapeutic products, which is the most important value driver for the Company", stated Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "The positive outcome of the MOR103 study and the progress of our partnered pipeline underscore the strength of our business model. We look forward to further progress in the months and years ahead."
Highlights of the Third Quarter
* MorphoSys delivered positive safety and efficacy results from a phase 1b/2a study of MOR103 in rheumatoid arthritis patients.
* MorphoSys and the University of Melbourne published preclinical data on the role of GM-CSF in inflammatory, arthritic and osteoarthritic pain.
* Roche highlighted progress in developing the HuCAL antibody gantenerumab in Alzheimer's disease at its Investor R&D Day.
* MorphoSys's partner OncoMed initiated a phase 1b/2 clinical trial with HuCAL antibody OMP-59R5 in advanced pancreatic cancer.
* MorphoSys's partner Bayer HealthCare received Orphan Drug Designation for the HuCAL-based antibody conjugate BAY 94-9343 in the USA for the treatment of mesothelioma.
* The product portfolio at MorphoSys matured further and remains one of the industry's broadest antibody pipelines: at the end of the quarter, MorphoSys's partnered and proprietary pipeline comprised 76 programs, of which 21 are in clinical development.
| |Nine Months |Nine Months | | | | |Ended |Ended | | | |In EURO million |Sep 30, 2012|Sep 30, 2011|Q3 2012|Q3 2011| +-------------------------------+------------+------------+-------+-------+ | | | | | | +-------------------------------+------------+------------+-------+-------+ | | | | | | | | | | | | |Group Revenues | 48.9| 83.7| 15.9| 17.1| +-------------------------------+------------+------------+-------+-------+ |of which success-based payments| 1.9| 32.2| 0.0| 1.0| +-------------------------------+------------+------------+-------+-------+ |of which AbD Serotec | 13.7| 14.1| 4.9| 4.7| +-------------------------------+------------+------------+-------+-------+ |Total Operating Expenses | 51.3| 64.1| 16.3| 20.6| +-------------------------------+------------+------------+-------+-------+ |EBIT | (2.3)| 18.0| (0.4)| (3.4)| +-------------------------------+------------+------------+-------+-------+ |Net Profit/(Loss) | (1.2)| 13.0| (0.2)| (2.0)| +-------------------------------+------------+------------+-------+-------+ |EPS, diluted, in EURO | (0.05)| 0.56| (0.01)| (0.09)| +-------------------------------+------------+------------+-------+-------+ | | | | | |
"Our financial strength allows us to continue investing in proprietary R&D, the main value driver of MorphoSys," commented Jens Holstein, Chief Financial Officer of MorphoSys AG. "Our financial results are, however, increasingly dependent on milestone payments and the initiation of additional commercial agreements, leading to a higher volatility in revenues and earnings. Negotiations for additional commercial agreements took longer than originally anticipated and as a consequence are having a negative impact on our financial results for 2012."
Financial Review for First Nine Months of 2012 According to IFRS
Group revenues for the first nine months of 2012 were EUR 48.9 million (9-months 2011: EUR 83.7 million), the difference to the previous year largely reflecting a one-off payment received in Q1 2011 from Novartis for the successful installation of the HuCAL platform at the Novartis Institutes for BioMedical Research in Basel, Switzerland. Revenues in the Partnered Discovery segment comprised EUR 32.1 million in funded research and licensing fees (9-months 2011: EUR 35.7 million) and EUR 1.9 million in success-based payments (9-months 2011: EUR 32.2 million). The Proprietary Development segment recorded funded research revenues of EUR 1.2 million (9-months 2011: EUR 1.9 million). Assuming constant foreign exchange rates at the average rate of the first nine months of 2011, revenues in the Partnered Discovery and Proprietary Development segments would have remained almost unchanged at EUR 35.1 million. The AbD Serotec segment provided 28 % or EUR 13.7 million of total revenues (9-months 2011: EUR 14.1 million), a decrease of 3 %. Assuming constant foreign exchange rates at the average rate of the first nine months of 2011, revenues in the AbD Serotec segment would have amounted to EUR 12.9 million.
Total operating expenses for the first nine months of 2012 decreased by 20 % to EUR 51.3 million (9-months 2011: EUR 64.1 million). The decrease of EUR 12.8 million was mainly caused by reduced proprietary research and development (R&D) expenses in line with the Company's plans. Cost of goods sold (COGS), a line item specific to AbD Serotec, decreased by 13 % to EUR 4.8 million (9-months 2011: EUR 5.5 million). Total research and development expenses for the Group decreased by EUR 11.6 million to EUR 30.3 million (9-months 2011: EUR 41.9 million). The decrease in R&D expenses mainly resulted from a lower level of investment in proprietary product and technology development amounting to EUR 17.2 million (9-months 2011: EUR 26.1 million). Sales, general and administrative expenses decreased by 4 % to EUR 16.2 million (9-months 2011: EUR 16.8 million). Non-cash charges related to stock-based compensation are embedded in COGS, S,G&A and R&D expenses and amounted to EUR 1.0 million (9-months 2011: EUR 1.1 million).
For the first nine months of 2012, MorphoSys recorded earnings before interest and taxes (EBIT) of minus EUR 2.3 million (9-months 2011: EBIT of EUR 18.0 million). Partnered Discovery showed a segment EBIT of EUR 17.9 million (9-months 2011: EBIT of EUR 50.9 million) while the continued investment in proprietary development led to segment EBIT of minus EUR 13.1 million (9-months 2011: EBIT of minus EUR 22.9 million). The AbD Serotec segment recorded a gross profit margin of 65 %, in comparison to 61 % in the first nine months of 2011. The EBIT for AbD Serotec amounted to minus EUR 0.04 million (9-months 2011: EBIT of EUR 0.3 million).
For the first nine months of 2012, MorphoSys recorded a net loss after taxes of EUR 1.2 million compared to a net profit of EUR 13.0 million in the same period of the previous year, the difference again being predominantly due to the one-off payment received in Q1 2011. The resulting diluted net loss per share for the first nine months of 2012 was EUR 0.05 (9-months 2011: diluted net profit of EUR 0.56).
On September 30, 2012, MorphoSys's cash, securities and interest-bearing assignable loans amounted to EUR 137.5 million (December 31, 2011: EUR 134.4 million). Net cash inflow from operations in the first nine months of 2012 amounted to EUR 2.4 million (2011: net cash inflow EUR 36.1 million). The number of issued shares at September 30, 2012 was 23,308,622, compared to 23,112,167 shares at December 31, 2011.
Financial Review of the Third Quarter of 2012 (IFRS)
In the third quarter of 2012, revenues were EUR 15.9 million, compared to EUR 17.1 million in the same quarter of 2011. Earnings before interest and taxes amounted to minus EUR 0.4 million, compared to an EBIT of minus EUR 3.4 million in the same period of 2011. A net loss of EUR 0.2 million was achieved in the third quarter of 2012, compared to a net loss of EUR 2.0 million during the same period in 2011.
Outlook for 2012
As stated in the past, revenues in 2012 are increasingly dependent on success-based milestones in existing therapeutic antibody programs, new alliances or the expansion of existing alliances involving new technology platforms such as Slonomics and Ylanthia. In 2012, negotiations for additional commercial agreements took longer than originally anticipated. In addition, the uncertainties of government fiscal deficits led to a reduction of funding for the research market, leading to lower sales in the AbD Serotec unit.
Therefore, MorphoSys updates its financial guidance for the Group for 2012. The company expects Group revenues to be in the range of EUR 70-75 million, thus being slightly below the original guidance of EUR 75-80 million. In terms of EBIT for the Group, it is expected to be around the lower end of the original guidance of EUR 1-5 million. At the time of the publication of the 9-months 2012 report, certain income-generating events are expected to materialize before the end of the year, the timely conclusion of which is important for reaching the 2012 financial guidance.
This guidance currently does not include a successful out-licensing of any of the Company's proprietary development programs. The scope and the timing of such events is difficult to predict and therefore not included in the financial projections.
Investment in proprietary research and development in 2012 remains unchanged and will be approximately EUR 20-25 million.
MorphoSys will hold a public conference call and webcast today at 02:00 p.m. CET (08:00 a.m. EST, 01:00 p.m. GMT) to present the Second Quarter Results 2012 and report on current developments.
Dial-in number for the Conference Call (listen-only): Germany: +49 89 2444 32975 For U.K. residents: +44 20 3003 2666 For U.S. residents: +1 202 204 1514
Please dial in 10 minutes before the beginning of the conference.
In addition, MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com.
A live webcast, slides, webcast replay and transcript will be made available at http://www.morphosys.com.
Approximately two hours after the press conference, a slide-synchronized audio replay of the conference will be available on http://www.morphosys.com.
The complete 3(rd) Interim Report 2012 (January - September) is available on our website (HTML and PDF): http://www.morphosys.com/FinancialReports
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
3rd Interim Report 2012 (PDF): http://hugin.info/130295/R/1655606/535015.pdf
Media Release (PDF): http://hugin.info/130295/R/1655606/535014.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
For more information, please contact:
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
Aug. 28, 2015 10:00 AM EDT
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
Aug. 28, 2015 09:38 AM EDT
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Aug. 28, 2015 07:45 AM EDT Reads: 389
Through WebRTC, audio and video communications are being embedded more easily than ever into applications, helping carriers, enterprises and independent software vendors deliver greater functionality to their end users. With today’s business world increasingly focused on outcomes, users’ growing calls for ease of use, and businesses craving smarter, tighter integration, what’s the next step in delivering a richer, more immersive experience? That richer, more fully integrated experience comes about through a Communications Platform as a Service which allows for messaging, screen sharing, video...
Aug. 28, 2015 07:30 AM EDT Reads: 538
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
Aug. 28, 2015 03:00 AM EDT Reads: 341
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of IoT applications and projects. Business operations, IT, and data scientists need advanced analytics t...
Aug. 28, 2015 12:30 AM EDT Reads: 337
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and analyzed? As an area of investment, how might a retail company move towards an innovation methodolo...
Aug. 27, 2015 06:15 PM EDT Reads: 390
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Aug. 27, 2015 01:00 PM EDT Reads: 292
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Treloar, President and COO of Bebaio, will explore examples of brands transforming their businesses by t...
Aug. 27, 2015 11:30 AM EDT Reads: 156
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of technology leadership, Micron's memory solutions enable the world's most innovative computing, consumer,...
Aug. 27, 2015 10:00 AM EDT Reads: 128
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevOps to advance innovation and increase agility. Specializing in designing, imple...
Aug. 26, 2015 08:00 AM EDT Reads: 166
Akana has announced the availability of the new Akana Healthcare Solution. The API-driven solution helps healthcare organizations accelerate their transition to being secure, digitally interoperable businesses. It leverages the Health Level Seven International Fast Healthcare Interoperability Resources (HL7 FHIR) standard to enable broader business use of medical data. Akana developed the Healthcare Solution in response to healthcare businesses that want to increase electronic, multi-device access to health records while reducing operating costs and complying with government regulations.
Aug. 26, 2015 07:00 AM EDT
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Aug. 3, 2015 06:45 PM EDT Reads: 781
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducted a live demonstration of how quickly application development can happen when the need to comply wit...
Aug. 2, 2015 11:15 AM EDT Reads: 542
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
Aug. 1, 2015 10:00 AM EDT Reads: 472
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Architect for the Internet of Things and Intelligent Systems, described how to revolutionize your archit...
Jul. 30, 2015 07:30 PM EDT Reads: 1,557
MuleSoft has announced the findings of its 2015 Connectivity Benchmark Report on the adoption and business impact of APIs. The findings suggest traditional businesses are quickly evolving into "composable enterprises" built out of hundreds of connected software services, applications and devices. Most are embracing the Internet of Things (IoT) and microservices technologies like Docker. A majority are integrating wearables, like smart watches, and more than half plan to generate revenue with APIs within the next year.
Jul. 30, 2015 02:30 PM EDT Reads: 272
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Opening Keynote at 16th Cloud Expo, Sandy Carter, IBM General Manager Cloud Ecosystem and Developers, and a Social Business Evangelist, d...
Jul. 30, 2015 12:00 PM EDT Reads: 2,217
In his keynote at 16th Cloud Expo, Rodney Rogers, CEO of Virtustream, discussed the evolution of the company from inception to its recent acquisition by EMC – including personal insights, lessons learned (and some WTF moments) along the way. Learn how Virtustream’s unique approach of combining the economics and elasticity of the consumer cloud model with proper performance, application automation and security into a platform became a breakout success with enterprise customers and a natural fit for the EMC Federation.
Jul. 30, 2015 09:00 AM EDT Reads: 2,309
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of profound change in the industry.
Jul. 29, 2015 03:00 PM EDT Reads: 1,437